Gene therapy injection aims to slow vision loss in rare eye disease

This early-stage trial tests a single injection of a gene therapy drug called UGX202 in 6 adults with advanced retinitis pigmentosa, a genetic condition that causes vision loss. The main goal is to check if the treatment is safe and tolerable over 52 weeks. Researchers will also look for early signs that it might help preserve or improve eyesight.